Xofigo Generic Name & Formulations
Radium Ra 223 dichloride 1000 kBq/mL (27 microcurie/mL) with a total radioactivity of 6000 kBq/vial (162 microcurie/vial) at the reference date; IV injection.
Alpha particle-emitting radioactive therapeutic agent.
Single-dose vials (6mL)—1
Treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Xofigo Dosage and Administration
See full labeling. Administer by slow IV over 1 min. 50kBq (1.35 microcurie) per kg given at 4 week intervals for 6 injections.
<18yrs: not established.
Xofigo Boxed Warnings
Not for use in females. Bone marrow suppression. Perform hematologic evaluation at baseline and prior to every dose. Before 1st dose, the ANC should be ≥1.5×109/L, platelets ≥100×109/L and hemoglobin ≥10g/dL. Before subsequent doses, the ANC should be ≥1×109/L and platelets ≥50×109/L; discontinue if no recovery within 6–8 weeks after last dose despite receiving supportive care. Monitor closely if evidence of compromised bone marrow reserve. Discontinue if life-threatening complications occur despite supportive care for bone marrow failure. Monitor oral intake and fluid status carefully. Embryo-fetal toxicity. Advise males (use condoms) and female partners of reproductive potential to use effective contraception during and 6 months after completion. Pregnancy. Nursing mothers: not studied.
Concomitant chemotherapy: not established. Discontinue if concomitant with chemotherapy, other systemic radioisotopes or hemibody external radiotherapy.
Xofigo Adverse Reactions
Nausea, diarrhea, vomiting, peripheral edema, anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia.
Xofigo Clinical Trials
Xofigo Patient Counseling